Peptide Library

FDA-approved

Bones & muscles

Zilucoplan

Evidence

FDA approved

Class

Complement C5 inhibitor macrocyclic peptide

/

Zilucoplan

KEY TAKEAWAY

Zilucoplan is a 15-amino-acid macrocyclic peptide that blocks complement protein C5. It is sold as Zilbrysq. The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Complement C5 inhibitor macrocyclic peptide

Approved for

Generalized myasthenia gravis in adults with anti-AChR antibodies

Key fact

The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Zilucoplan is a 15-amino-acid macrocyclic peptide that blocks complement protein C5. It is sold as Zilbrysq.

How it works

How it works

By binding C5, it stops the complement system from attacking the nerve-muscle junction in myasthenia gravis.

Regulatory status

Regulatory status

The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.

What it is used for

What it is used for

Generalized myasthenia gravis in adults with anti-AChR antibodies.

Side effects and risks

Side effects and risks

The label carries a boxed warning for serious meningococcal infections, so vaccination and monitoring are required.

Citations

Citations

U.S. FDA prescribing information for Zilucoplan. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo